Restoration of methotrexate-suppressed oxazolone-induced contact sensitivity with levamisole. 1978

D E Griswold, and D T Walz

The effect of levamisole upon cell-mediated immunity was investigated using the oxazolone-induced contact sensitivity response in immunosuppressed and nonimmunosuppressed C57Bl male mice. Mice were sensitized to oxazolone on day 0, and where appropriate, methotrexate (1 mg/kg, p.o.) was administered on days 1 and 2. On day 3, levamisole (5--50 mg/kg, p.o., base) was administered. One hour later, the animals were challenged with oxazolone on the left hindpaw. Twenty-four hours after challenge, the resulting edema was read plethysmographically. Levamisole, in the absence of immunosuppression, had no significant effect upon the oxazolone response whereas, in the face of immunosuppression, restoration of oxazolone responsiveness was observed. These results were suggested to be due to (1) the ability of levamisole to stimulate opposing suppressor and effector components of the oxazolone response coupled with (2) an apparent alteration of suppressor influence by methotrexate allowing levamisole to enhance an unencumbered effector cell population.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010081 Oxazolone Immunologic adjuvant and sensitizing agent. 2-Phenyl-4-(ethoxymethylene)oxazol-5-one,4-Ethoxymethylene-2-phenyloxazolone,4 Ethoxymethylene 2 phenyloxazolone
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

D E Griswold, and D T Walz
January 1982, International archives of allergy and applied immunology,
D E Griswold, and D T Walz
August 1994, International journal of immunopharmacology,
D E Griswold, and D T Walz
January 1981, International archives of allergy and applied immunology,
D E Griswold, and D T Walz
January 1983, Cancer immunology, immunotherapy : CII,
D E Griswold, and D T Walz
October 1985, Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology,
D E Griswold, and D T Walz
February 2018, Histology and histopathology,
D E Griswold, and D T Walz
January 1982, International journal of immunopharmacology,
D E Griswold, and D T Walz
January 1987, International journal of immunopharmacology,
D E Griswold, and D T Walz
October 1979, Infection and immunity,
Copied contents to your clipboard!